Brokers Set Expectations for Aprea Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at Wedbush reduced their Q1 2024 EPS estimates for shares of Aprea Therapeutics in a research report issued on Tuesday, March 26th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.75) per share for the quarter, down from their prior forecast of ($0.20). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Aprea Therapeutics’ Q2 2024 earnings at ($0.81) EPS, Q3 2024 earnings at ($0.87) EPS, Q4 2024 earnings at ($0.93) EPS, FY2024 earnings at ($3.36) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.46) EPS and FY2027 earnings at ($0.17) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $6.69 on Friday. The firm’s fifty day moving average price is $6.39 and its 200-day moving average price is $5.01. Aprea Therapeutics has a fifty-two week low of $2.78 and a fifty-two week high of $8.85.

Hedge Funds Weigh In On Aprea Therapeutics

A number of large investors have recently added to or reduced their stakes in APRE. BNP Paribas Arbitrage SNC purchased a new position in shares of Aprea Therapeutics in the third quarter valued at about $40,000. Millennium Management LLC increased its position in shares of Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after acquiring an additional 43,293 shares during the period. Jane Street Group LLC purchased a new position in shares of Aprea Therapeutics in the second quarter valued at about $54,000. Geode Capital Management LLC purchased a new position in shares of Aprea Therapeutics in the second quarter valued at about $74,000. Finally, Vanguard Group Inc. increased its position in shares of Aprea Therapeutics by 76.4% in the third quarter. Vanguard Group Inc. now owns 27,341 shares of the company’s stock valued at $114,000 after acquiring an additional 11,840 shares during the period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Bernd R. Seizinger bought 6,860 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average price of $7.29 per share, for a total transaction of $50,009.40. Following the transaction, the director now directly owns 33,685 shares in the company, valued at $245,563.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 9,870 shares of company stock worth $71,952 in the last 90 days. 20.90% of the stock is owned by company insiders.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.